TransCode Therapeutics has reported significant progress in its Phase 1a clinical trial of TTX-MC138, an innovative RNA-based therapeutic targeting microRNA-10b in metastatic cancer. In the trial, thirteen patients have received at least one dose across four dosing levels, with researchers observing no significant toxicities.
The preliminary results are promising, with eight patients still participating in the study and two demonstrating stable disease after seven months. Early pharmacokinetic and pharmacodynamic data suggest target engagement and a dose-response relationship consistent with preclinical research findings.
These results are critically important because they represent a potential breakthrough in treating metastatic cancers. The therapy specifically targets microRNA-10b, a biomarker associated with cancer metastasis, offering a novel approach to addressing aggressive tumor spread.
The company plans to advance the trial to Phase 1b, which will provide further evaluation of the therapy's safety and anti-tumor activity. This progression indicates scientific confidence in the initial outcomes and the potential of RNA-based therapeutic strategies.
The research highlights the emerging potential of RNA therapeutics in oncology, presenting a targeted approach that could offer new hope for patients with challenging metastatic cancers.
